Table 1

The rate of permanent discontinuation of different ICIs because of treatment-related adverse events

IndicationDrugDiscontinuation rate, %
Metastatic melanomaIpilimumab
Nivolumab
Ipilimumab+nivolumab
Pembrolizumab		14.860, 9.461
7.760
36.460
6.961 (every 3 weeks), 461 (every 2 weeks)
Metastatic renal cell cancerIpilimumab+nivolumab
Nivolumab		2262
863
NSCLCPembrolizumab964

  • ICI, immune checkpoint inhibition.